The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension
CHEST · 2026-07 · 170 (1) · 214-222
DOI: 10.1016/j.chest.2026.02.014 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift CHEST, 2026-07. Verfasst von Matthew R Lammi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: mlammi@lsuhsc.edu. Hauptthemen laut MEDLINE: Antihypertensive Agents, Epoprostenol, Hypertension, Pulmonary, Lung Diseases, Interstitial. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Pulmonary Fibrosis Foundation, National Heart, Lung, and Blood Institute, National Scleroderma Foundation.
Abstract (Originalsprache)
BACKGROUND N-terminal pro-brain natriuretic peptide (NT-proBNP) is a commonly used biomarker of right heart function in patients with pulmonary hypertension. RESEARCH QUESTION What is the minimal important difference (MID) for NT-proBNP change in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension related to interstitial lung disease (PH-ILD), and is achievement of the MID associated with improved clinical outcomes? STUDY DESIGN AND METHODS Data from two placebo-controlled trials were used to determine the MID for PAH (FREEDOM-EV: oral treprostinil) and PH-ILD (INCREASE: inhaled treprostinil). Distributional-based methods were used to calculate the MID for percent change from baseline in NT-proBNP in the FREEDOM-EV and INCREASE trials at 12 and 16 weeks, respectively. The associations between MID achievement and clinical outcomes were assessed by occurrence of a clinical worsening event in FREEDOM-EV or 6-minute walk distance (6MWD) improvement in INCREASE. RESULTS Complete data were available for 638 participants in FREEDOM-EV and 250 participants in INCREASE. The median MID for NT-proBNP change in the FREEDOM-EV and INCREASE trials was a 48% improvement. Participants with PAH who achieved the MID at 12 weeks were 52% less likely to have a clinical worsening event during long-term follow-up (HR, 0.48; 95% CI, 0.31-0.75, p=0.001). Participants with PH-ILD who achieved the MID at 16 weeks had a relative improvement in 6MWD of 40 meters (95% CI, 14-66 meters, p=0.003) compared with those who did not achieve the MID. INTERPRETATION The estimated MID for short-term NT-proBNP improvement in PAH and PH-ILD is remarkably similar at 48%. Achievement of the MID for NT-proBNP change is strongly associated with clinically important outcomes in both PAH and PH-ILD, demonstrating that measuring NT-proBNP change over 12-16 weeks can be informative for prognosis and may be useful for decisions regarding treatment escalation in individuals with PAH and PH-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: mlammi@lsuhsc.edu.
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
- United Therapeutics Corp, Research Triangle Park, Raleigh, NC.
- Department of Statistics, North Carolina State University, Raleigh, NC.
Förderung
- Pulmonary Fibrosis Foundation
- National Heart, Lung, and Blood Institute
- National Scleroderma Foundation
- National Heart Lung and Blood Institute Division of Intramural Research
Zitieren
APA
Lammi, M. R., Khan, S. L., Rao, Y., Zhao, W., Balasubramanian, A., & Mathai, S. C. (2026). The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension. CHEST, 170(1), 214-222. https://doi.org/10.1016/j.chest.2026.02.014
Vancouver
Lammi MR, Khan SL, Rao Y, Zhao W, Balasubramanian A, Mathai SC. The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension. CHEST. 2026;170(1):214-222. doi:10.1016/j.chest.2026.02.014
BibTeX
@article{Lammi2026,
author = {Lammi, Matthew R and Khan, Sarah L and Rao, Youlan and Zhao, Wei and Balasubramanian, Aparna and Mathai, Stephen C},
title = {The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension},
journal = {CHEST},
year = {2026},
volume = {170},
number = {1},
pages = {214--222},
doi = {10.1016/j.chest.2026.02.014}
}
EUVIMED